Cargando…
Impact of (18)F-fluciclovine PET/CT on salvage radiotherapy plans for men with recurrence of prostate cancer postradical prostatectomy
Imaging options to localize biochemical recurrence (BCR) of prostate cancer after radical prostatectomy (RP) are limited, especially at low prostate-specific antigen (PSA) levels. The FALCON study evaluated the impact of (18)F-fluciclovine PET/CT on management plans for patients with BCR. Here, we e...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754096/ https://www.ncbi.nlm.nih.gov/pubmed/34669678 http://dx.doi.org/10.1097/MNM.0000000000001501 |
_version_ | 1784632201705422848 |
---|---|
author | Payne, Heather Bomanji, Jamshed Bottomley, David Scarsbrook, Andrew F. Teoh, Eugene J. |
author_facet | Payne, Heather Bomanji, Jamshed Bottomley, David Scarsbrook, Andrew F. Teoh, Eugene J. |
author_sort | Payne, Heather |
collection | PubMed |
description | Imaging options to localize biochemical recurrence (BCR) of prostate cancer after radical prostatectomy (RP) are limited, especially at low prostate-specific antigen (PSA) levels. The FALCON study evaluated the impact of (18)F-fluciclovine PET/CT on management plans for patients with BCR. Here, we evaluate salvage radiotherapy decisions in patients post-RP. METHODS: We conducted a subgroup analysis of post-RP patients enrolled in FALCON who had a prescan plan for salvage radiotherapy (± androgen-deprivation therapy). Patients’ treatment plans post-(18)F-fluciclovine PET/CT were compared with their prescan plans. Fisher exact test was used to determine the impact of PSA and Gleason sum on positivity and anatomical patterns of uptake. RESULTS: Sixty-five (63%) FALCON patients had undergone RP. Of these, 62 (median PSA, 0.32 ng/mL) had a prescan plan for salvage radiotherapy. Twenty-one (34%) had (18)F-fluciclovine-avid lesions. Disease was confined to the prostate bed in 11 patients (52%) and to the pelvis in a further 5 (24%), while 5 (24%) had extrapelvic findings. Trends towards more disseminated disease with increasing PSA or Gleason sum were observed but did not reach statistical significance. Postscan, 25 (40%) patients had a management change; 17 (68%) were changed to the treatment modality (8 to systemic therapy, 8 to active surveillance, 1 other) and 8 (32%) were radiotherapy field modifications. CONCLUSIONS: Incorporating (18)F-fluciclovine PET/CT into treatment planning may help identify patients suitable for salvage radiotherapy, help augment planned radiotherapy to better target lesions and support the clinician to optimise patient management. |
format | Online Article Text |
id | pubmed-8754096 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-87540962022-01-14 Impact of (18)F-fluciclovine PET/CT on salvage radiotherapy plans for men with recurrence of prostate cancer postradical prostatectomy Payne, Heather Bomanji, Jamshed Bottomley, David Scarsbrook, Andrew F. Teoh, Eugene J. Nucl Med Commun Original Articles Imaging options to localize biochemical recurrence (BCR) of prostate cancer after radical prostatectomy (RP) are limited, especially at low prostate-specific antigen (PSA) levels. The FALCON study evaluated the impact of (18)F-fluciclovine PET/CT on management plans for patients with BCR. Here, we evaluate salvage radiotherapy decisions in patients post-RP. METHODS: We conducted a subgroup analysis of post-RP patients enrolled in FALCON who had a prescan plan for salvage radiotherapy (± androgen-deprivation therapy). Patients’ treatment plans post-(18)F-fluciclovine PET/CT were compared with their prescan plans. Fisher exact test was used to determine the impact of PSA and Gleason sum on positivity and anatomical patterns of uptake. RESULTS: Sixty-five (63%) FALCON patients had undergone RP. Of these, 62 (median PSA, 0.32 ng/mL) had a prescan plan for salvage radiotherapy. Twenty-one (34%) had (18)F-fluciclovine-avid lesions. Disease was confined to the prostate bed in 11 patients (52%) and to the pelvis in a further 5 (24%), while 5 (24%) had extrapelvic findings. Trends towards more disseminated disease with increasing PSA or Gleason sum were observed but did not reach statistical significance. Postscan, 25 (40%) patients had a management change; 17 (68%) were changed to the treatment modality (8 to systemic therapy, 8 to active surveillance, 1 other) and 8 (32%) were radiotherapy field modifications. CONCLUSIONS: Incorporating (18)F-fluciclovine PET/CT into treatment planning may help identify patients suitable for salvage radiotherapy, help augment planned radiotherapy to better target lesions and support the clinician to optimise patient management. Lippincott Williams & Wilkins 2021-10-19 2022-02 /pmc/articles/PMC8754096/ /pubmed/34669678 http://dx.doi.org/10.1097/MNM.0000000000001501 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Original Articles Payne, Heather Bomanji, Jamshed Bottomley, David Scarsbrook, Andrew F. Teoh, Eugene J. Impact of (18)F-fluciclovine PET/CT on salvage radiotherapy plans for men with recurrence of prostate cancer postradical prostatectomy |
title | Impact of (18)F-fluciclovine PET/CT on salvage radiotherapy plans for men with recurrence of prostate cancer postradical prostatectomy |
title_full | Impact of (18)F-fluciclovine PET/CT on salvage radiotherapy plans for men with recurrence of prostate cancer postradical prostatectomy |
title_fullStr | Impact of (18)F-fluciclovine PET/CT on salvage radiotherapy plans for men with recurrence of prostate cancer postradical prostatectomy |
title_full_unstemmed | Impact of (18)F-fluciclovine PET/CT on salvage radiotherapy plans for men with recurrence of prostate cancer postradical prostatectomy |
title_short | Impact of (18)F-fluciclovine PET/CT on salvage radiotherapy plans for men with recurrence of prostate cancer postradical prostatectomy |
title_sort | impact of (18)f-fluciclovine pet/ct on salvage radiotherapy plans for men with recurrence of prostate cancer postradical prostatectomy |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754096/ https://www.ncbi.nlm.nih.gov/pubmed/34669678 http://dx.doi.org/10.1097/MNM.0000000000001501 |
work_keys_str_mv | AT payneheather impactof18ffluciclovinepetctonsalvageradiotherapyplansformenwithrecurrenceofprostatecancerpostradicalprostatectomy AT bomanjijamshed impactof18ffluciclovinepetctonsalvageradiotherapyplansformenwithrecurrenceofprostatecancerpostradicalprostatectomy AT bottomleydavid impactof18ffluciclovinepetctonsalvageradiotherapyplansformenwithrecurrenceofprostatecancerpostradicalprostatectomy AT scarsbrookandrewf impactof18ffluciclovinepetctonsalvageradiotherapyplansformenwithrecurrenceofprostatecancerpostradicalprostatectomy AT teoheugenej impactof18ffluciclovinepetctonsalvageradiotherapyplansformenwithrecurrenceofprostatecancerpostradicalprostatectomy |